Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 7/2018

01-08-2018 | Original Article

Clinical application of 99mTc-HYNIC-TOC SPECT/CT in diagnosing and monitoring of pancreatic neuroendocrine neoplasms

Authors: Junyan Xu, Yi Li, Xiaoping Xu, Jiangang Zhang, Yingjian Zhang, Xianjun Yu, Dan Huang

Published in: Annals of Nuclear Medicine | Issue 7/2018

Login to get access

Abstract

Objective

Our aim of this research was to determine the value of SPECT/CT with 99mTc-HYNIC-TOC for evaluation of the pancreatic masses which were suspected as neuroendocrine neoplasms and follow-up of patients with pancreatic neuroendocrine neoplasms.

Methods

We retrospectively analyzed 184 patients who performed 99mTc-HYNIC-TOC SPECT/CT. All the patients were divided into two groups: one for assessment of diagnostic efficiency for pancreatic suspected masses (n = 140) and another for monitoring recurrence after surgery (n = 44). The image findings acquired at 2 h postinjection were compared to final diagnoses from pathological results and clinical follow-up. Then, the correlation between ratios of tumor-to-background (TBR) and tumor grade was analyzed.

Results

In group 1, 95/140 (67.9%) patients were confirmed as neuroendocrine neoplasms including 85 neuroendocrine tumors and 10 neuroendocrine carcinomas. Patient-based analysis showed that the sensitivity, specificity and accuracy of diagnosing neuroendocrine neoplasms with SPECT/CT were 81.1, 84.4 and 82.1%. There was significant difference of TBRs among G1, G2 and G3 (F = 3.175, P = 0.048). In group 2, 22/44 (50.0%) patients occurred metastasis mainly in liver. The sensitivity, specificity and accuracy of monitoring recurrence were 87.0, 100 and 93.2%.

Conclusions

99mTc-HYNIC-TOC SPECT/CT is a reliable method of diagnosing and monitoring of pancreatic neuroendocrine neoplasms, especially neuroendocrine tumors.
Literature
1.
Rust E, Hubele F, Marzano E, Goichot B, Pessaux P, Kurtz JE, et al. Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice. Cancer Imaging. 2012;12:173 – 84.CrossRefPubMedPubMedCentral
2.
3.
D’Haese JG, Tosolini C, Ceyhan GO, Kong B, Esposito I, Michalski CW, et al. Update on surgical treatment of pancreatic neuroendocrine neoplasms. World J Gastroenterol. 2014;20:13893–8.CrossRefPubMedPubMedCentral
4.
Balachandran A, Tamm EP, Bhosale PR, Patnana M, Vikram R, Fleming JB, et al. Pancreatic neuroendocrine neoplasms: diagnosis and management. Abdom Imaging. 2013;38:342–57.CrossRefPubMed
5.
Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836 – 46.CrossRefPubMed
6.
Olsen JO, Pozderac RV, Hinkle G, Hill T, O’Dorisio TM, Schirmer WJ, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med. 1995;25:251 – 61.CrossRefPubMed
7.
Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, et al. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med. 2001;42:1134–8.PubMed
8.
Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, et al. 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients. J Nucl Med. 2015;56:847 – 54.CrossRefPubMed
9.
Melo IB, Ueda LT, Araujo EB, Muramoto E, Barboz MF, Mengatti J, et al. Tecnetium-99m as alternative to produce somatostatin-labeled derivatives: comparative biodistribution evaluation with 111In-DTPA-octreotide. Cell Mol Biol (Noisy-le-grand). 2010;56:31–6.
10.
Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med. 2000;27:1318–25.CrossRefPubMed
11.
Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44:708 – 16.PubMed
12.
Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R, Maecke HR, Huszno B, Pach D, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience. Eur J Nucl Med Mol Imaging. 2006;33:1123–33.CrossRefPubMed
13.
Bangard M, Behe M, Guhlke S, Otte R, Bender H, Maecke HR, et al. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-d-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-d-Phe1-octreotide. Eur J Nucl Med. 2000;27:628 – 37.CrossRefPubMed
14.
Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. J Nucl Med. 2000;41:1114–9.PubMed
15.
Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017;29:11 – 6.CrossRefPubMed
16.
Trogrlic M, Tezak S. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors. Nucl Med Rev Cent East Eur. 2016;19:74–80.CrossRefPubMed
17.
Qiao Z, Zhang J, Jin X, Huo L, Zhu Z, Xing H, et al. 99mTc-HYNIC-TOC imaging in the evaluation of pancreatic masses which are potential neuroendocrine tumors. Clin Nucl Med. 2015;40:397–400.CrossRefPubMed
18.
de la Cueva L, Lloro P, Sangros MJ, Lopez Velez L, Navarro P, Sarria L, et al. Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy. Clin Transl Oncol. 2017;19:915–20.CrossRefPubMed
19.
Sepulveda-Mendez J, de Murphy CA, Pedraza-Lopez M, Murphy-Stack E, Rojas-Bautista JC, Gonzalez-Trevino O. Specificity and sensitivity of (9)(9)mTc-EDDA/HYNIC-Tyr(3)-octreotide ((9)(9)mTc-TOC) for imaging neuroendocrine tumors. Nucl Med Commun. 2012;33:69–79.CrossRefPubMed
20.
Garai I, Barna S, Nagy G, Forgacs A. Limitations and pitfalls of 99mTc-EDDA/HYNIC-TOC (Tektrotyd) scintigraphy. Nucl Med Rev Cent East Eur. 2016;19:93 – 8.CrossRefPubMed
21.
Peter L, Sanger J, Hommann M, Baum RP, Kaemmerer D. Molecular imaging of late somatostatin receptor-positive metastases of renal cell carcinoma in the pancreas by 68 Ga DOTATOC PET/CT: a rare differential diagnosis to multiple primary pancreatic neuroendocrine tumors. Clin Nucl Med. 2014;39:713–6.CrossRefPubMed
22.
Niu N, Mao X, Jing H, Li F. Parathyroid hyperplasia shown on (99 m)Tc-HYNIC-TOC scan. Clin Nucl Med. 2013;38:294–6.CrossRefPubMed
23.
Morgat C, Velayoudom-Cephise FL, Schwartz P, Guyot M, Gaye D, Vimont D, et al. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. Eur J Nucl Med Mol Imaging. 2016;43:1258–66.CrossRefPubMed
24.
Hasegawa S, Kobayashi N, Tokuhisa M, Goto A, Takano S, Takada Y, et al. Clinical usefulness of somatostatin receptor scintigraphy in japanese patients with gastroenteropancreatic neuroendocrine tumors. Digestion. 2017;96:13–20.CrossRefPubMed
25.
Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of 68 Ga-DOTANOC and 68 Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54:364–72.CrossRefPubMed
26.
Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, et al. Comparison of the impact of 68 Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors. J Nucl Med. 2017;58:91–6.CrossRefPubMed
27.
Deroose CM, Hindie E, Kebebew E, Goichot B, Pacak K, Taieb D, et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med. 2016;57:1949–56.CrossRefPubMed
28.
Madrzak D, Mikolajczak R, Kaminski G. Influence of PET/CT 68 Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT. Nucl Med Rev Cent East Eur. 2016;19:88–92.CrossRefPubMed
Metadata
Title
Clinical application of 99mTc-HYNIC-TOC SPECT/CT in diagnosing and monitoring of pancreatic neuroendocrine neoplasms
Authors
Junyan Xu
Yi Li
Xiaoping Xu
Jiangang Zhang
Yingjian Zhang
Xianjun Yu
Dan Huang
Publication date
01-08-2018
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 7/2018
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-018-1266-8

Other articles of this Issue 7/2018

Annals of Nuclear Medicine 7/2018 Go to the issue

Original Article

Is 18F-FDG PET/CT useful for the differential diagnosis of solitary pulmonary nodules in patients with idiopathic pulmonary fibrosis?

Original Article

Reconstruction/segmentation of attenuation map in TOF-PET based on mixture models

Original Article

Reliable radiosynthesis of 4-[10B]borono-2-[18F]fluoro-l-phenylalanine with quality assurance for boron neutron capture therapy-oriented diagnosis

Original Article

Optimal monochromatic color combinations for fusion imaging of FDG-PET and diffusion-weighted MR images

Original Article

Evaluation of the default-mode network by quantitative 15O-PET: comparative study between cerebral blood flow and oxygen consumption

Original Article

Effects of rs591323 on serotonin transporter availability in healthy male subjects